PV Bulletin

PRIME: Updated Guidance on Priority Medicines

The European Medicines Agency (EMA) has updated its guidance on the PRIME scheme, including new eligibility recommendations and procedural clarifications.

Primary source: Infographic - PRIME 5-year report highlights

PV Impact Brief

Urgency: HighConfidence: high

What changed

Updated guidance clarifies the PRIME scheme's eligibility for medicines that address unmet medical needs and introduces revised information on early support interactions between developers and EMA.

Why it matters

Understanding the updated guidance is crucial for Marketing Authorisation Holders (MAHs) and sponsors to effectively engage with EMA and align their pharmacovigilance strategies during the product development lifecycle, ultimately improving patient access to new therapies.

Action needed

MAHs and sponsors of priority medicines must review the updated PRIME guidance to ensure compliance with new interaction expectations, particularly regarding risk management planning and post-authorisation safety monitoring.

Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Signal ManagementCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

As necessary, aligned with future EMA updates.

Policy change details

Document type
Guideline
Policy status
revised
Publication date
2026-08-10
Policy change
The European Medicines Agency (EMA) has updated its guidance on the PRIME (PRIority MEdicines) scheme as of August 10, 2026. The update includes revised information on new features of the scheme and eligibility recommendations for priority medicines that address unmet medical needs. This procedural update clarifies the interactions between developers and the EMA throughout the development lifecycle.

Key changes

Updated guidance on the features of the PRIME scheme and release of new eligibility recommendations adopted at the CHMP meeting of July 2026. The updates likely clarify the process for seeking early support and scientific advice for high-priority medicines.

Affected workflows

Signal ManagementCountry Compliance

Responsible groups

Regulatory AffairsPharmacovigilance OperationsClinical Development

PV impact

MAHs and sponsors of priority medicines should review the updated PRIME guidance to understand potential changes in early interaction expectations, particularly regarding risk management planning (RMP) and post-authorisation safety monitoring. While primarily a development-stage scheme, PRIME status leads to intensified scientific advice and accelerated assessment, requiring robust PV strategy alignment early in the product lifecycle.

View regulator source

Source document details

Exact policy details

Launch Date of PRIME Scheme
March 2016
Applies to: All medicines targeting unmet medical needs.
The European Medicines Agency (EMA) launched the PRIME scheme in March 2016. · p. 4 · High · Source
Eligibility Criteria for PRIME
Medicines must address an unmet medical need and provide a major therapeutic advantage.
Applies to: All applicants seeking PRIME support.
Medicines eligible for PRIME support shall target diseases where there is an unmet medical need, i.e. for which there exists no satisfactory method of diagnosis, prevention or treatment. · p. 5 · High · Source
Response Time for Applications
EMA responds after 40 days.
Applies to: All applications submitted for PRIME.
EMA responds after 40 days. · p. 2 · High · Source
Total Requests for PRIME Since Launch
177 requests received and assessed.
Applies to: Reflects overall interest in the PRIME scheme.
177 requests for eligibility to PRIME received and assessed since launch in March 2016. · p. 3 · High · Source
Acceptance Rate of Requests
21% of requests accepted.
Applies to: Indicates selectivity of the PRIME scheme.
21% of requests have been accepted in the scheme, totalling 36 medicines accepted into PRIME scheme. · p. 3 · High · Source
Submission Readiness Meeting Timeline
9-12 months ahead of marketing authorization application.
Applies to: For PRIME candidates preparing for marketing authorization.
organises a submission readiness meeting 9-12 months ahead of the intended marketing authorisation application submission. · p. 2 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Aug 10, 2026

Full briefing

Practical implication

MAHs and sponsors of priority medicines must review the updated PRIME guidance to ensure compliance with new interaction expectations, particularly regarding risk management planning and post-authorisation safety monitoring.

The EMA revised its guidance on the PRIME scheme as of August 10, 2026. The update provides clearer expectations for developers of priority medicines regarding early support, risk management planning (RMP), and post-authorisation safety monitoring. This procedural update aims to enhance the development of drugs addressing unmet medical needs and involves intensified scientific advice and accelerated assessment processes.

What changed: Updated guidance clarifies the PRIME scheme's eligibility for medicines that address unmet medical needs and introduces revised information on early support interactions between developers and EMA.

Why it matters: Understanding the updated guidance is crucial for Marketing Authorisation Holders (MAHs) and sponsors to effectively engage with EMA and align their pharmacovigilance strategies during the product development lifecycle, ultimately improving patient access to new therapies.

Practical implication: MAHs and sponsors of priority medicines must review the updated PRIME guidance to ensure compliance with new interaction expectations, particularly regarding risk management planning and post-authorisation safety monitoring.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Guideline#revised#policy-change#Guidance#firecrawl-policy-agent#European Medicines Agency

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward